THROMBOMAX 12MIU/1.5mg
Avoid platelet transfusions in successive chemotherapies with Thrombomax! Thrombocytopenia may compromise cancer treatment, causing chemotherapy dose reductions, schedule alterations, or the need for platelet transfusions. Thrombomax has been rendered safe and effective as it helps in reducing treatment-associated thrombocytopenia and the need for platelet transfusions in patients who undergo dose intensive chemotherapy, and thus it permits chemotherapy to be administered as planned at intended doses and thereby maximize the potential for a successful outcome. [3]
Thrombomax Injection
Generic Name: Oprelvekin (Recombinant Human Interleukin-11)
Indications
- Prevention of severe thrombocytopenia in adult patients with non-myeloid malignancies.
- Reduction of the need for platelet transfusions following myelosuppressive chemotherapy.
- Applicable to patients at high risk of severe thrombocytopenia during chemotherapy.
Strength
1.5 mg per vial
Pack Size
Single-use vial
Dosage Form
Lyophilized powder for solution for subcutaneous injection
Categories
Pharmaceuticals
Therapeutic Class
Thrombopoietic Growth Factors